HS-276
Modify Date: 2025-08-25 22:26:12
HS-276 structure
|
Common Name | HS-276 | ||
|---|---|---|---|---|
| CAS Number | 2767422-72-8 | Molecular Weight | 419.52 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C24H29N5O2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of HS-276HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research[1]. |
| Name | HS-276 |
|---|
| Description | HS-276 is an orally active, potent and highly selective TAK1 inhibitor, with a Ki of 2.5 nM. HS-276 shows significant inhibition of TAK1, CLK2, GCK, ULK2, MAP4K5, IRAK1, NUAK, CSNK1G2, CAMKKβ-1, and MLK1, with IC50 values of 8.25, 29, 33, 63, 125, 264, 270, 810, 1280, and 5585 nM, respectively. HS-276 can be used for rheumatoid arthritis (RA) research[1]. |
|---|---|
| Related Catalog | |
| Target |
IRAK1:264 nM (IC50) IRAK4:2500 nM (IC50) |
| In Vitro | HS-276 reduces expression of TNF, IL-6, and IL-1β in a dose-dependent manner, with IC50 values of 138, 201, and 234 nM, respectively[1]. |
| In Vivo | HS-276 (CIA mouse model of inflammatory arthritis, 50 mg/kg, IP, daily for 6 days) reduces inflammation, pannus, cartilage damage (CD), bone resorption (BR), and periosteal bone formation (PBF) histological manifestations[1]. HS-276 (CD-1 mice, 30 mg/kg, Oral gavage, once) shows excellent bioavailability in mice with a Cmax of 3.68 μM and %F of 98.1%[1]. |
| References |
| Molecular Formula | C24H29N5O2 |
|---|---|
| Molecular Weight | 419.52 |